Kronos Bio (KRON) announced that it will present preclinical data from its p300 KAT inhibitor program for multiple myeloma at the American Society of Hematology, ASH, Annual Meeting taking place in San Diego, California from December 7 to 10, 2024. Data demonstrates Kronos Bio’s approach to targeting oncogenic transcription factors and the strong relationship between IRF4 and p300 in Multiple Myeloma
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRON:
- KRON Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Kronos Bio announces preclinical data from p300 KAT inhibitor program
- Kronos Bio to present data from p300 KAT inhibitor program
- Kronos Bio nominates development candidate for Sjogren’s Disease
- Kronos Bio to present preclinical data from p300 KAT inhibitor program
Questions or Comments about the article? Write to editor@tipranks.com